Sign In
Buy CSTL
$24.69
-0.795 (-3.12%)
At Close: Jul 24, 2026
Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence r
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
07:00am, Wednesday, 15'th Apr 2026
FRIENDSWOOD, Texas, April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will re
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
07:00am, Friday, 10'th Apr 2026
FRIENDSWOOD, Texas, April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has rec
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside
04:04pm, Monday, 30'th Mar 2026
Castle Biosciences, Inc. is positioned as a leader in precision cancer diagnostics, notably with DecisionDx-Melanoma, offering scalable, clinically validated solutions. CSTL reported strong Q4/FY2025
Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
02:22am, Monday, 23'rd Mar 2026
Shares of Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten research firms that are currently covering the company, MarketBeat rep
Castle today announced the publication of results from a prospective, multicenter study evaluating DecisionDx-Melanoma's integrated SLNB test result.
Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy
Castle will share new data evaluating DecisionDx-Melanoma's i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
04:30pm, Tuesday, 03'rd Mar 2026
FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it wil
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down – Here’s Why
03:48am, Sunday, 01'st Mar 2026
Shares of Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) gapped down before the market opened on Friday. The stock had previously closed at $31.88, but opened at $29.87. Castle Biosciences
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
08:57pm, Thursday, 26'th Feb 2026
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates
07:01pm, Thursday, 26'th Feb 2026
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.32 per share a year ago.
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
04:05pm, Thursday, 26'th Feb 2026
2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and w
